Companies / Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Financials · FY2025
Ownership
133.8M shares outstanding · as of Jul 24, 2026
Ownership
| Insiders | 0.22% | 290,317 |
| 10%+ / strategic | 16.25% | 21,745,061 |
| Institutions | 88.54% | 118,468,924 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 17
View all →| Insider | % of shares | Shares |
|---|---|---|
Greenstreet YvonneCEOChief Executive Officer · Director | 0.07% | 95,695 |
Poulton Jeffrey V.EVP, Chief Financial Officer | 0.05% | 61,805 |
Tanguler TolgaEVP, Chief Commercial Officer | 0.03% | 34,297 |
Schulman Amy WDirector | 0.02% | 24,049 |
Fitzgerald Kevin JosephCSO & EVP, Head of Research | 0.02% | 20,569 |
Garg PushkalEVP Chief R&D | 0.01% | 18,693 |
Supran BryanEVP, CLO and Secretary | 0.01% | 14,565 |
McLaughlin MelissaChief Human Resources Officer | <0.01% | 9,443 |
Ausiello Dennis ADirector | <0.01% | 1,582 |
Hamburg Margaret aDirector | <0.01% | 1,582 |
Institutional holders 861
View all →| Holder | Value | % of shares |
|---|---|---|
| $6.48B | 12.18% | |
| $6.32B | 11.88% | |
| $5.39B | 10.13% | |
| $3.28B | 8.15% | |
| $2.70B | 5.07% | |
| $1.88B | 3.53% | |
| $1.07B | 2.66% | |
| $895.82M | 1.68% | |
| $884.57M | 1.99% | |
| $861.25M | 1.62% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Norges Bank 13F manager | Exit | — | $-895.82M | -2.3M -100.00% | — | high |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Add | — | $455.43M | +1.4M +223.41% | 1,992,577 1.49% of shares | high |
| Q1 2026 as of | Arrowstreet Capital, Limited Partnership 13F manager | Exit | — | $-448.22M | -1.1M -100.00% | — | high |
| Q4 2025 as of | Bank of America Corp /De 13F manager | Trim | — | $-323.41M | -813K -54.28% | 685,177 0.51% of shares | high |
| Q1 2026 as of | Clearbridge Investments, LLC 13F manager | Add | — | $251.14M | +759K +127.14% | 1,356,036 1.01% of shares | high |
| Q1 2026 as of | D. E. Shaw & Co., Inc. 13F manager | Add | — | $203.34M | +615K +138.26% | 1,059,062 0.79% of shares | high |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | — | $181.78M | +549K +99.90% | 1,099,318 0.82% of shares | high |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | — | $152.56M | +507K +4.87% | 10,907,675 8.15% of shares | high |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Fmr LLC | Passive13G/A | — |
| Capital Research Global Investors | Passive13G/A | — |
| Capital World Investors | Passive13G/A | — |
| Vanguard Capital Management | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| ALNY | — | 02043Q107 |